Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…Abstract Number: 2309 • 2018 ACR/ARHP Annual Meeting
Implementation of a Primary Prevention, Population-Based Virtual Osteoporosis Clinic Dramatically Increases the Number of Rural Veterans Receiving Osteoporosis Screening and Treatment
Background/Purpose: The delivery of osteoporosis services is sub-optimal nationally and throughout the Veterans Affairs (VA) healthcare system and particularly poor for rural Veterans. To meet…Abstract Number: 2367 • 2017 ACR/ARHP Annual Meeting
The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis
Background/Purpose: The role of glucocorticoids (GCs) in the treatment of rheumatoid arthritis (RA) is widely debated. GCs stimulate bone resorption and impair bone formation. Inflammatory…Abstract Number: 2369 • 2017 ACR/ARHP Annual Meeting
Relationship of Bone Mineral Density and Inflammatory Burden with Carotid Plaque Formation in Rheumatoid Arthritis: A 5-Year Prospective Study
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease. The incidence of the cardiovascular (CV) disease is significantly increased in patients with RA…Abstract Number: 2379 • 2017 ACR/ARHP Annual Meeting
Effect of DKK-1 and Osteoprotegerin on Bone Mass in Tightly Controlled Rheumatoid Arthritis
Background/Purpose: To analyze the association between osteoprotegerin (OPG) and Dickkopf-related protein 1 (DKK-1) and the annual percent change (Δ%) in bone mineral density (BMD) in patients…Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…Abstract Number: 2514 • 2017 ACR/ARHP Annual Meeting
When Should Lateral Dexa be Used to Measure Spine Bone Mineral Density in Axial Spondyloarthritis Patients: A Cross-Sectional Study
Background/Purpose: Osteoporosis and vertebral fractures are recognized complications in axial spondyloarthritis (axSpA). Anteroposterior (AP) DEXA is commonly used to assess spinal bone mineral density (BMD)…Abstract Number: 324 • 2017 ACR/ARHP Annual Meeting
The Predictors of the Efficacy of Denosumab, a Monoclonal Antibody to RANK Ligand, on Osteoporosis in Rheumatoid Arthritis Patients from Japanese Multicenter Study
Background/Purpose: Although early intensive treatment has improved medication of rheumatoid arthritis (RA), treatment for osteoporosis (OP) in RA patient will be more important. Here, we…Abstract Number: 2911 • 2017 ACR/ARHP Annual Meeting
Low Appendicular Bone Mass Predicts Mortality in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is a multi-system disease which causes joint damage and is associated with increased cardiovascular (CV) morbidity and osteoporosis. Our purpose is…Abstract Number: 330 • 2017 ACR/ARHP Annual Meeting
Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: Minimal 10-Year Follow-up
Background/Purpose: To investigate the long-term change in bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Methods: In a longitudinal study of 40 patients…Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…Abstract Number: 334 • 2017 ACR/ARHP Annual Meeting
Comparison of Outcomes in Osteoporosis in Patients on Denosumab between Standard and Non-Standard Dosing Intervals
Background/Purpose: Denosumab (Dmab) is an antiresorptive agent with an approximate half-life of 26 days and according to the prescribing information the recommended dose is 60…Abstract Number: 1218 • 2017 ACR/ARHP Annual Meeting
Caffeine Consumption and Risk of Osteoporosis: A Cross Sectional Study of 3, 210 Patients from the National Health and Nutrition Examination Survey
Background/Purpose: Adenosine regulates bone metabolism. In vitro studies suggest that direct stimulation of the adenosine A2A receptor increases osteoblasts and diminishes osteoclasts, and thus inhibition…Abstract Number: 1222 • 2017 ACR/ARHP Annual Meeting
Impact of Bariatric Surgery on Bone Mineral Density : Observational Study of 110 Patients Followed up in a Specialised Centre for the Treatment of Obesity in France
Background/Purpose: Bariatric surgery is used to treat severe obesity. We aimed to investigate the incidence of significant bone mineral density (BMD) loss at 6 and…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »